Bio-Thera, Intas extend partnership for golimumab biosimilar
BAT2506 is a proposed biosimilar of golimumab, developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that specifically targets tumour necrosis factor alpha (TNF-α), a key pro-inflammatory
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.